Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2025)
Denali Therapeutics (DNLI) posted quarterly Other Non-Current Liabilities of $379000.0 for Q3 2023, little changed year-over-year from $379000.0 in Q3 2022, and little changed quarter-over-quarter from $379000.0 in Q2 2023.
Powered by 
Analysis
Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Denali Therapeutics (DNLI) has reported Other Non-Current Liabilities for 7 consecutive years, with $379000.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Other Non-Current Liabilities changed 0.0% year-over-year to $379000.0; the TTM figure through Sep 2023 stood at $379000.0 (changed 0.0% YoY), while the FY2022 annual figure was $379000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities steadied at $379000.0 in Q3 2023 per DNLI's latest filing, from $379000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $701000.0 in Q4 2020 and bottomed at $379000.0 in Q4 2019.
- Historically, Other Non-Current Liabilities has averaged $451894.7 across 5 years, with a median of $379000.0 in 2019.
- Annual changes were most pronounced in 2019 — Other Non-Current Liabilities jumped 211.29% — and 2021, when it plunged 45.93%.
- Denali Therapeutics' Other Non-Current Liabilities stood at $379000.0 in 2019, then surged by 84.96% to $701000.0 in 2020, then slumped by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
- Business Quant data shows DNLI's Other Non-Current Liabilities at $379000.0 in Q3 2023, $379000.0 in Q2 2023, and $379000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 4.18 Bn | 4.18 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 10.44 Mn |
| Mar 31, 2025 | 16.73 Mn |
| Sep 30, 2024 | 3.94 Mn |
| Sep 30, 2023 | 379,000.00 |
| Jun 30, 2023 | 379,000.00 |
| Mar 31, 2023 | 379,000.00 |
| Dec 31, 2022 | 379,000.00 |
| Sep 30, 2022 | 379,000.00 |
| Jun 30, 2022 | 379,000.00 |
| Mar 31, 2022 | 379,000.00 |
| Dec 31, 2021 | 379,000.00 |
| Sep 30, 2021 | 701,000.00 |
| Jun 30, 2021 | 701,000.00 |
| Mar 31, 2021 | 701,000.00 |
| Dec 31, 2020 | 701,000.00 |
| Sep 30, 2020 | 379,000.00 |
| Jun 30, 2020 | 379,000.00 |
| Mar 31, 2020 | 379,000.00 |
| Dec 31, 2019 | 379,000.00 |